Article ID Journal Published Year Pages File Type
9346450 Ophthalmology 2005 10 Pages PDF
Abstract
Dorzolamide reduced IOP by 15% to 22% throughout the 5 years of the trial. However, the EGPS failed to detect a statistically significant difference between medical therapy and placebo in reducing the incidence of POAG among a large population of OHT patients at moderate risk for developing POAG, because placebo also significantly and consistently lowered IOP.
Related Topics
Health Sciences Medicine and Dentistry Ophthalmology
Authors
,